PepGen is a clinical-stage biotechnology company developing oligonucleotide therapies for severe neuromuscular and neurologic diseases using its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, which employs cell-penetrating peptides to improve the cellular uptake and nuclear delivery of therapeutic molecules across muscle and nervous tissue. The company's lead program targets myotonic dystrophy type 1, a rare neuromuscular disorder, with a mechanism designed to correct defective RNA processing rather than broadly degrading disease-related transcripts. PepGen does not yet generate revenue and relies on advancing its clinical pipeline toward potential approvals, after which it would establish a specialty sales organization to market therapies to the concentrated patient populations affected by its target diseases.